Literature DB >> 24750431

Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis.

R Tortelli1, M Copetti, M Ruggieri, R Cortese, R Capozzo, A Leo, E D'Errico, M Mastrapasqua, S Zoccolella, F Pellegrini, I L Simone, G Logroscino.   

Abstract

BACKGROUND AND
PURPOSE: To evaluate whether cerebrospinal fluid (CSF) neurofilament light chain (NFL) levels could predict the time to generalization (TTG) in amyotrophic lateral sclerosis (ALS).
METHODS: Cerebrospinal fluid NFL levels of 37 cases of sporadic ALS were measured and the time of symptom spreading from spinal or bulbar localization to both (TTG) was evaluated in all patients.
RESULTS: Kaplan-Meier analysis showed a short TTG in patients with high NFL levels (log-rank test chi-squared = 19.4, P < 0.0001). In a multivariate regression model patients with NFL levels above the median had an eight-fold higher risk of generalization (adjusted hazard ratio 7.9, 95% confidence interval 2.9-21.4, P < 0.0001) compared with those with NFL levels below the median.
CONCLUSIONS: This study shows that in sporadic ALS NFL, a marker of neurodegeneration, is correlated with TTG, a clinical intermediate parameter of survivorship.
© 2014 The Author(s) European Journal of Neurology © 2014 EAN.

Entities:  

Keywords:  ALS; CSF; biomarkers

Mesh:

Substances:

Year:  2014        PMID: 24750431     DOI: 10.1111/ene.12421

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  19 in total

1.  Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease.

Authors:  Alessandra Gaiani; Ilaria Martinelli; Luca Bello; Giorgia Querin; Marco Puthenparampil; Susanna Ruggero; Elisabetta Toffanin; Annachiara Cagnin; Chiara Briani; Elena Pegoraro; Gianni Sorarù
Journal:  JAMA Neurol       Date:  2017-05-01       Impact factor: 18.302

Review 2.  Paving the path to HIV neurotherapy: Predicting SIV CNS disease.

Authors:  Sarah E Beck; Suzanne E Queen; Kenneth W Witwer; Kelly A Metcalf Pate; Lisa M Mangus; Lucio Gama; Robert J Adams; Janice E Clements; M Christine Zink; Joseph L Mankowski
Journal:  Eur J Pharmacol       Date:  2015-03-24       Impact factor: 4.432

3.  Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis.

Authors:  Antonio Scarafino; Eustachio D'Errico; Alessandro Introna; Angela Fraddosio; Eugenio Distaso; Irene Tempesta; Antonella Morea; Antonella Mastronardi; Rosaria Leante; Maddalena Ruggieri; Mariangela Mastrapasqua; Isabella Laura Simone
Journal:  J Neurol       Date:  2018-08-16       Impact factor: 4.849

Review 4.  TDP-43 and Cytoskeletal Proteins in ALS.

Authors:  Moritz Oberstadt; Joseph Claßen; Thomas Arendt; Max Holzer
Journal:  Mol Neurobiol       Date:  2017-05-02       Impact factor: 5.590

Review 5.  Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?

Authors:  Katharine A Nicholson; Merit E Cudkowicz; James D Berry
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 6.  Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis.

Authors:  Lucas T Vu; Robert Bowser
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 7.  ALS biomarkers for therapy development: State of the field and future directions.

Authors:  Michael Benatar; Kevin Boylan; Andreas Jeromin; Seward B Rutkove; James Berry; Nazem Atassi; Lucie Bruijn
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

Review 8.  Neurofilament Light Chain as a Biomarker, and Correlation with Magnetic Resonance Imaging in Diagnosis of CNS-Related Disorders.

Authors:  Zahra Alirezaei; Mohammad Hossein Pourhanifeh; Sarina Borran; Majid Nejati; Hamed Mirzaei; Michael R Hamblin
Journal:  Mol Neurobiol       Date:  2019-08-05       Impact factor: 5.590

Review 9.  New developments and future opportunities in biomarkers for amyotrophic lateral sclerosis.

Authors:  Xueping Chen; Hui-Fang Shang
Journal:  Transl Neurodegener       Date:  2015-09-30       Impact factor: 8.014

10.  CSF neurofilament light chain reflects corticospinal tract degeneration in ALS.

Authors:  Ricarda A L Menke; Elizabeth Gray; Ching-Hua Lu; Jens Kuhle; Kevin Talbot; Andrea Malaspina; Martin R Turner
Journal:  Ann Clin Transl Neurol       Date:  2015-05-25       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.